Martindale Pharma launches new Caffiene product for AoP

Martindale Pharma has announced the launch of Caffeine 5mg/ml Oral Solution, a new product for the treatment of apnoea of prematurity (AoP).

The new liquid presentation of the therapy is packaged in a more conveniently-sized bottle than previous iterations and is the first caffeine product designed specifically for oral administration to be approved for UK sale.

It is used by hospitals with special care baby units to stimulate breathing in pre-term babies suffering from AoP, a condition that causes infants to stop breathing for 15 to 20 seconds during sleep.

This can occur due to underdevelopment of the parts of the central nervous system that control breathing, but it can also be linked to the effect of illnesses and drugs.

Richard de Souza, chief executive officer of Martindale Pharma, said: "We have expanded our range of licensed Caffeine solutions to include this larger volume container for oral administration and therefore better ease of use."

Earlier this year, the company was named one of the top 100 fastest-growing companies backed by private equity in 2012.